Oramed(US:ORMP) Prnewswireยท2025-10-23 12:55Core Insights - Oramed Pharmaceuticals has made significant advancements in its operations and strategic initiatives, focusing on long-term shareholder value creation [2][8] - The company has identified high-responder subgroups in its oral insulin program, showing potential for over 1% reduction in HbA1c, which enhances its regulatory and commercial positioning [4][17] - Oramed is pursuing a 60-patient trial in the U.S. to validate its oral insulin formulation, aiming for cost-effective evidence generation [5][17] Oral Insulin Program - The oral insulin program has shown promising results in high-responder subgroups, particularly among participants with lower BMI and older demographics [4] - A new U.S.-based trial is being initiated to validate the oral insulin formulation and refine patient selection criteria for future regulatory submissions [5] Investment Portfolio - Oramed has strategically invested in various biomedical companies, including a $99.5 million loan to Scilex Holdings, which has returned $95.5 million to date, with total expected returns of approximately $170 million [7][9] - The company invested $36.9 million in Alpha Tau Medical, with a current valuation of approximately $64.8 million, reflecting a gain of $27.1 million [9][10] - Oramed has also invested $7 million in BioXcel Therapeutics and $1.5 million in Pelthos Therapeutics, with significant gains realized in both investments [12][13] Growth Initiatives - The company is actively pursuing partnerships with strong companies to unlock market potential and drive value creation [15] - Oramed's diversified investment strategy has led to substantial returns while maintaining focus on its core oral insulin program [3][17] Financial Performance - As of September 30, 2025, Oramed's total cash and assets have grown to approximately $210 million, demonstrating effective capital deployment despite investing $17.8 million in R&D [16]